24/7 Customer Support

+1 718 473 0872

Imexpharm - Company Report, 2011

  • January 2011
  • 11 pages

Download This Report Now!

We value your privacy and will never rent or sell your email address.
Privacy Policy by TRUSTe

  • Segment Coverage

    Drug And Medicatio...  

  • Geographic Coverage

    Vietnam  

  • Type of data

    Company Financials  

    Forecast  

  • IMP 1
  • Imexpharm (IMP - HoSE: FY2011 results and FY2012 outlook - FY2011 a little under
  • target while forward growth prospects looks rather anemic for now. 1
  • Investment Conclusion 2
  • Sales by segment 3
  • COMPANY PROFILE 7
  • Scope of business 7
  • Sales breakdown in FY2011 7
  • Products, Services and Market 7
  • Ownership structure as of Feb. 2012 7
  • Position in the industry 7
  • Business strategy 8
  • Qualifications 8
  • Earnings model 1
  • Snapshot 2
  • COGS by segment 3
  • Gross profit by segment 3
  • Net financial income 4
  • FY2012 Outlook 5
  • Company History 7
  • Trading segment 3% 7
  • SWOT 8
  • FINANCIAL RATIO 9
  • ROA - ROE movement (%) 10
  • Sales - Net profit movement (VNDmil) 10
  • Unit: VNDmillion 10

Refine your search results

Purchase Reports From Reputable Market Research Publishers

World Drug and Medication: Typhoid Fever – Pipeline Review, H2 2011

World Drug and Medication: Typhoid Fever – Pipeline Review, H2 2011

  • $ 2 000
  • Company report
  • August 2014
  • by Global Markets Direct

Ependymoma – Pipeline Review, H2 2011 Global Industries Direct’s, 'Ependymoma - Pipeline Review, H2 2011', provides an overview of the Ependymoma therapeutic pipeline. This report provides data on ...

World Drug and Medication: Uveitis - Pipeline Review, H2 2011

World Drug and Medication: Uveitis - Pipeline Review, H2 2011

  • $ 2 000
  • Company report
  • August 2014
  • by Global Markets Direct

This report provides information on the therapeutic development for Uveitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved ...

Drug and Medication in China: Novo Nordisk A/S – Product Pipeline Review – H2 2011

Drug and Medication in China: Novo Nordisk A/S – Product Pipeline Review – H2 2011

  • $ 1 500
  • Company report
  • June 2014
  • by Global Markets Direct

The report includes data on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. This report is built using data and information sourced from ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.